Sign in
Taking people in United StatesPhase 3

Sodium Thiosulfate to Reduce Hearing Loss in Children With Medulloblastoma

Tests sodium thiosulfate in children with a brain tumor to reduce cisplatin-related hearing loss.

Key facts

Who runs it
Children's Oncology Group
Where
Akron, Albany, Ann Arbor, Atlanta, Aurora, Austin, Baltimore, Birmingham, Boston, Buffalo, Chapel Hill, Charlotte, Charlottesville, Chicago, Cincinnati, Cleveland, Columbia, Columbus, Corpus Christi, Dallas, Danville, Dayton, Des Moines, Detroit, El Paso, Fargo, Fort Myers, Grand Rapids, Greenville, Hartford, Hollywood, Honolulu, Indianapolis, Iowa City, Jackson, Jacksonville, Kansas City, Knoxville, Little Rock, Loma Linda, Long Beach, Los Angeles, Louisville, Madera, Madison, Marshfield, Miami, Milwaukee, Minneapolis, Mobile, Nashville, New Brunswick, New Haven, New Hyde Park, New Orleans, New York, Newark, Norfolk, Oakland, Oklahoma City, Omaha, Orange, Orlando, Paterson, Pensacola, Peoria, Philadelphia, Phoenix, Pittsburgh, Portland, Providence, Richmond, Rochester, Royal Oak, Sacramento, San Antonio, San Diego, San Francisco, Seattle, Sioux Falls, Spokane, Springfield, St Louis, St. Petersburg, Stony Brook, Syracuse, Tacoma, Tampa, The Bronx, Toledo, Valhalla, Washington D.C., Wilmington, and Winston-Salem, United StatesSee the 106 sitesAlso in 1 other country, 5 sites
Trial code
Registry title
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Status
Recruiting
Phase
Phase 3
People taking part
225 people, planned
Started
20 Feb 2023
Expected to end
31 Dec 2029
Type of study
Interventional
Treatments tested
  • Audiometric Test
  • Auditory Brainstem Response
  • Biospecimen Collection
  • Cisplatin
  • Cyclophosphamide
  • Lomustine
  • Magnetic Resonance Imaging
  • Quality-of-Life Assessment
  • Radiation Therapy
  • Sodium Thiosulfate
  • Survey Administration
  • Vincristine
Record updated
25 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people aged 4 to 21 with newly diagnosed average-risk or low-risk medulloblastoma, a brain cancer. It tests sodium thiosulfate to reduce hearing loss from cisplatin.

Age
4 to 21 years
Sex
All sexes can join.
Disease stage
Newly diagnosed medulloblastoma with no spread (M0), no diffuse anaplastic histology, and average-risk or low-risk molecular features. Residual tumor must be 1.5 cm² or smaller. Negative lumbar CSF cytology.
Earlier treatment
No earlier radiation therapy or chemotherapy. Only surgery and/or corticosteroids are allowed before the trial.
Biomarker or test result
Average-risk: SHH (p53wt, GLI2 normal, MYCN normal, no chromosome 14q loss), Group 3 (MYC normal, no isochromosome 17q), or Group 4 (no chromosome 11 loss). Low-risk features: Group 4 with chromosome 11 loss. Normal hearing (SIOP grade 0) in at least one ear.

Main reasons for not taking part

  • Cancer that has spread, seen on MRI or in the spinal fluid
  • Unable to have a lumbar puncture
  • Known allergy to sodium thiosulfate, sulfates/sulfites or other thiol agents
  • Pregnant, or breastfeeding and planning to continue
  • Weight of 10 kg (22 lb) or less

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • PRE-ENROLLMENT: Patients must be ≥ 4 years and ≤ 21 years of age at the time of enrollment
  • PRE-ENROLLMENT: Patient is suspected to have newly-diagnosed medulloblastoma by institutional diagnosis; Please note: Patients with a pending result of CSF cytology tests are eligible for NCI-2014-02057 (APEC14B1-Central Nervous System [CNS]) and CNS/Medulloblastoma Pre Enrollment Eligibility Screening
  • PRE-ENROLLMENT: The patient and/or their parents or legal guardians must have signed informed consent for APEC14B1 Part A - Eligibility Screening and consent for the Molecular Characterization Initiative (MCI)
  • PRE-ENROLLMENT: The required specimens are projected to be submitted under APEC14B1-CNS as soon as possible, preferably within 5 days of definitive surgery
  • PRE-ENROLLMENT: All patients must have rapid central pathology review under APEC14B1-CNS prior to study enrollment on ACNS2031 step 1 in order to avoid discordant diagnoses and to verify diagnosis criterion for treatment on ACNS2031; Note: Patients with a pending result of CSF cytology tests are eligible for the rapid central pathology screening review. Confirmation of CSF negativity is needed for enrollment on the ACNS2031 protocol
  • PRE-ENROLLMENT: All patients must have rapid central molecular screening review under APEC14B1-CNS prior to study enrollment on ACNS2031 step 1, in order to avoid discordant diagnoses and to verify diagnosis criterion for treatment on ACNS2031
  • PRE-ENROLLMENT: All patients who have histopathology confirmed must have rapid central imaging screening review under APEC14B1 prior to study enrollment on ACNS2031 step 1; Note: Patients must not have metastatic disease on cranial or spinal MRI. Patients with > 1.5 cm\^2 residual tumor after initial surgical resection may undergo a second surgical resection prior to subsequent therapy to render them eligible for this study. The day of the second resection to remove residual tumor will be regarded as the day of definitive surgery (Day 0) and must be within a month (31 days) of the initial resection
  • PRE-ENROLLMENT: All patients who have histopathology confirmed must have rapid central audiology review under APEC14B1-CNS prior to study enrollment on ACNS2031 step 1
  • Patients must be >= 4 years and =< 21 years of age at the time of enrollment
  • Patients must be newly diagnosed and have eligibility confirmed by rapid central pathology and molecular screening reviews performed on APEC14B1 and via the Molecular Characterization Initiative
  • Average-risk cohort; Clinico-pathologic criteria:; M0 disease; No diffuse anaplastic histology AND; Molecular criteria:; SHH, p53wt, GLI2 normal, MYCN normal, no chromosome 14q loss; Group 3, MYC normal, no isochromosome 17q; Group 4, no chromosome 11 loss
  • Low-risk features cohort; Clinico-pathologic criteria:; M0 disease; No diffuse anaplastic histology AND; Molecular criteria:; Group 4, chromosome 11 loss
  • Patients must have negative lumbar CSF cytology; Note: CSF cytology for staging should be performed no sooner than 14 days post operatively to avoid false positive CSF. Ideally, CSF should be obtained between day 14 and day 21 to allow for final staging status before enrollment onto the study. Patients with positive CSF cytology obtained 0 to 14 days after surgery should have cytology repeated to determine eligibility and final CSF status. Patients with negative CSF cytology from lumbar puncture obtained 0 to 14 days after surgery do not need cytology repeated. Patients with negative CSF cytology from lumbar puncture obtained prior to surgery do not need cytology repeated post-operatively
  • Patients must have eligibility confirmed by Rapid Central Imaging Review performed on APEC14B1. Patients must have =< 1.5 cm\^2 cross-sectional area of residual tumor. Whole brain MRI with and without gadolinium and spine MRI with gadolinium must be performed
  • Patients must weigh > 10 kg
  • Patients must be enrolled, and protocol therapy must be projected to begin, no later than 31 days after definitive diagnostic surgery (day 0)
  • Peripheral absolute neutrophil count (ANC) >= 1000/uL (within 7 days prior to enrollment)
  • Platelet count >= 100,000/uL (transfusion independent) (within 7 days prior to enrollment)
  • Hemoglobin >= 8.0 g/dL (may receive red blood cell count [RBC] transfusions) (within 7 days prior to enrollment)
  • A serum creatinine (within 7 days prior to enrollment) based on age/sex as follows:; 4 to < 6 years (age); 0.8 mg/dL (male) 0.8 mg/dL (female); 6 to < 10 years (age); 1 mg/dL (male) 1 mg/dL (female); 10 to < 13 years (age); 1.2 mg/dL (male) 1.2 mg/dL (female); 13 to < 16 years (age); 1.5 mg/dL (male) 1.4 mg/dL (female); >= 16 years (age); 1.7 mg/dL (male) 1.4 mg/dL (female) OR a 24 hour urine Creatinine clearance >= 70 mL/min/1.73 m\^2 (within 7 days prior to enrollment) OR a glomerular filtration rate (GFR) >= 70 mL/min/1.73 m\^2 (within 7 days prior to enrollment). GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard); Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment)
  • Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L (within 7 days prior to enrollment); Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
  • Central nervous system function defined as:; Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled; Patients must not be in status epilepticus, a coma or assisted ventilation at the time of study enrollment
  • Auditory function defined as:; Patients must have normal hearing (defined as International Society of Pediatric Oncology [SIOP] grade 0) in at least one ear confirmed by rapid central audiology review performed on APEC14B1 prior to enrollment
  • All patients and/or their parents or legal guardians must sign a written informed consent
  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Who cannot take part

  • Patients must not have received any prior radiation therapy or chemotherapy (tumor-directed therapy) other than surgical intervention and/or corticosteroids
  • Pregnancy and Breastfeeding:; Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential; Lactating females who plan to breastfeed their infants; Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
  • Patients with metastatic disease by either MRI evaluation or lumbar CSF cytology are not eligible. Patients who are unable to undergo a lumbar puncture for assessment of CSF cytology are ineligible
  • Patients must not have any known hypersensitivity to STS, sulfates/sulfites, or other thiol agents (e.g., amifostine, n-acetylcysteine, MESNA, and captopril)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 4 and 21 years old?

Where in United States

Also in 1 other country, 5 sites

  • Children's Hospital Medical Center of AkronAkron, United StatesContact: Erin Wright (principal investigator)Taking people
  • Albany Medical CenterAlbany, United StatesContact: Lauren R. Weintraub (principal investigator)Taking people
  • C S Mott Children's HospitalAnn Arbor, United StatesContact: Andrea T. Franson (principal investigator)Taking people
  • Children's Healthcare of Atlanta - Arthur M Blank HospitalAtlanta, United StatesContact: Anna J. Janss (principal investigator)Taking people
  • Children's Hospital ColoradoAurora, United StatesContact: Holly B. Lindsay (principal investigator)Taking people
  • Dell Children's Medical Center of Central TexasAustin, United StatesContact: Shannon M. Cohn (principal investigator)Taking people
  • Johns Hopkins University/Sidney Kimmel Cancer CenterBaltimore, United StatesContact: Kenneth J. Cohen (principal investigator)Taking people
  • Sinai Hospital of BaltimoreBaltimore, United StatesContact: Jason M. Fixler (principal investigator)Taking people
  • Children's Hospital of AlabamaBirmingham, United StatesNo longer taking part
  • Dana-Farber Cancer InstituteBoston, United StatesContact: Ralph Salloum (principal investigator)Taking people
  • Massachusetts General Hospital Cancer CenterBoston, United StatesNo longer taking part
  • Roswell Park Cancer InstituteBuffalo, United StatesContact: Clare J. Twist (principal investigator)Taking people
  • UNC Lineberger Comprehensive Cancer CenterChapel Hill, United StatesContact: David E. Kram (principal investigator)Taking people
  • Carolinas Medical Center/Levine Cancer InstituteCharlotte, United StatesContact: Joel A. Kaplan (principal investigator)Taking people
  • University of Virginia Cancer CenterCharlottesville, United StatesContact: Brian C. Belyea (principal investigator)Taking people
  • University of IllinoisChicago, United StatesContact: Dipti S. Dighe (principal investigator)Taking people
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Peter M. de Blank (principal investigator)Taking people
  • Rainbow Babies and Childrens HospitalCleveland, United StatesContact: Duncan S. Stearns (principal investigator)Taking people
  • Prisma Health Richland HospitalColumbia, United StatesContact: Stuart L. Cramer (principal investigator)Taking people
  • Nationwide Children's HospitalColumbus, United StatesContact: Mark A. Ranalli (principal investigator)Taking people
  • Driscoll Children's HospitalCorpus Christi, United StatesContact: Nkechi I. Mba (principal investigator)Taking people
  • Medical City Dallas HospitalDallas, United StatesContact: Maurizio L. Ghisoli (principal investigator)Taking people
  • UT Southwestern/Simmons Cancer Center-DallasDallas, United StatesContact: Daniel C. Bowers (principal investigator)Taking people
  • Geisinger Medical CenterDanville, United StatesContact: Jagadeesh Ramdas (principal investigator)Taking people
  • Dayton Children's HospitalDayton, United StatesContact: Jordan M. Wright (principal investigator)Taking people
  • Blank Children's HospitalDes Moines, United StatesContact: Samantha L. Mallory (principal investigator)Taking people
  • Children's Hospital of MichiganDetroit, United StatesContact: Hamza Gorsi (principal investigator)Taking people
  • El Paso Children's HospitalEl Paso, United StatesContact: Benjamin Carcamo (principal investigator)Taking people
  • Sanford Broadway Medical CenterFargo, United StatesContact: Samuel J. Milanovich (principal investigator)Taking people
  • Golisano Children's Hospital of Southwest FloridaFort Myers, United StatesContact: Emad K. Salman (principal investigator)Taking people
  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's HospitalGrand Rapids, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • BI-LO Charities Children's Cancer CenterGreenville, United StatesContact: Aniket Saha (principal investigator)Taking people
  • East Carolina UniversityGreenville, United StatesContact: Andrea R. Whitfield (principal investigator)Taking people
  • Connecticut Children's Medical CenterHartford, United StatesContact: Michael S. Isakoff (principal investigator)Taking people
  • Memorial Regional Hospital/Joe DiMaggio Children's HospitalHollywood, United StatesContact: Iftikhar Hanif (principal investigator)Taking people
  • Kapiolani Medical Center for Women and ChildrenHonolulu, United StatesContact: Wade T. Kyono (principal investigator)Taking people
  • Riley Hospital for ChildrenIndianapolis, United StatesContact: Sandeep Batra (principal investigator)Taking people
  • University of Iowa/Holden Comprehensive Cancer CenterIowa City, United StatesContact: Andrew P. Groves (principal investigator)Taking people
  • University of Mississippi Medical CenterJackson, United StatesContact: Amanda Strobel (principal investigator)Taking people
  • Nemours Children's Clinic-JacksonvilleJacksonville, United StatesContact: Sridhi Patel (principal investigator)Taking people
  • Children's Mercy Hospitals and ClinicsKansas City, United StatesContact: Keith J. August (principal investigator)Taking people
  • East Tennessee Childrens HospitalKnoxville, United StatesContact: Susan E. Spiller (principal investigator)Taking people
  • Arkansas Children's HospitalLittle Rock, United StatesContact: Michael W. Bishop (principal investigator)Taking people
  • Loma Linda University Medical CenterLoma Linda, United StatesContact: Albert Kheradpour (principal investigator)Taking people
  • Miller Children's and Women's Hospital Long BeachLong Beach, United StatesContact: Jacqueline N. Casillas (principal investigator)Taking people
  • Children's Hospital Los AngelesLos Angeles, United StatesContact: Ashley S. Margol (principal investigator)Taking people
  • Norton Children's HospitalLouisville, United StatesContact: Michael J. Ferguson (principal investigator)Taking people
  • Valley Children's HospitalMadera, United StatesContact: Ruetima Titapiwatanakun (principal investigator)Taking people
  • University of Wisconsin Carbone Cancer Center - University HospitalMadison, United StatesContact: Nicholas J. Pytel (principal investigator)Taking people
  • Marshfield Medical Center-MarshfieldMarshfield, United StatesContact: Michelle A. Manalang (principal investigator)Taking people
  • Nicklaus Children's HospitalMiami, United StatesContact: Ziad A. Khatib (principal investigator)Taking people
  • University of Miami Miller School of Medicine-Sylvester Cancer CenterMiami, United StatesContact: Bradley Gampel (principal investigator)Taking people
  • Children's Hospital of WisconsinMilwaukee, United StatesContact: Sarah Rumler (principal investigator)Taking people
  • Children's Hospitals and Clinics of Minnesota - MinneapolisMinneapolis, United StatesContact: Michael K. Richards (principal investigator)Taking people
  • USA Health Strada Patient Care CenterMobile, United StatesContact: Hamayun Imran (principal investigator)Taking people
  • Vanderbilt University/Ingram Cancer CenterNashville, United StatesNo longer taking part
  • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University HospitalNew Brunswick, United StatesContact: Nehal S. Parikh (principal investigator)Taking people
  • Saint Peter's University HospitalNew Brunswick, United StatesContact: Nibal A. Zaghloul (principal investigator)Taking people
  • Yale UniversityNew Haven, United StatesContact: Asher M. Marks (principal investigator)Taking people
  • The Steven and Alexandra Cohen Children's Medical Center of New YorkNew Hyde Park, United StatesNo longer taking part
  • Children's Hospital New OrleansNew Orleans, United StatesContact: Maria C. Velez-Yanguas (principal investigator)Taking people
  • Laura and Isaac Perlmutter Cancer Center at NYU LangoneNew York, United StatesContact: Jessica Clymer (principal investigator)Taking people
  • Mount Sinai HospitalNew York, United StatesContact: Pamela R. Merola (principal investigator)Taking people
  • Newark Beth Israel Medical CenterNewark, United StatesContact: Teena Bhatla (principal investigator)Taking people
  • Children's Hospital of The King's DaughtersNorfolk, United StatesContact: Melissa S. Mark (principal investigator)Taking people
  • Kaiser Permanente-OaklandOakland, United StatesContact: Aarati V. Rao (principal investigator)Taking people
  • University of Oklahoma Health Sciences CenterOklahoma City, United StatesContact: Rene Y. McNall-Knapp (principal investigator)Taking people
  • Children's Hospital and Medical Center of OmahaOmaha, United StatesContact: Jill C. Beck (principal investigator)Taking people
  • University of Nebraska Medical CenterOmaha, United StatesContact: Jill C. Beck (principal investigator)Taking people
  • Children's Hospital of Orange CountyOrange, United StatesContact: Elyssa M. Rubin (principal investigator)Taking people
  • Arnold Palmer Hospital for ChildrenOrlando, United StatesContact: Zhongbo Hu (principal investigator)Taking people
  • Nemours Children's HospitalOrlando, United StatesContact: Sridhi Patel (principal investigator)Taking people
  • Saint Joseph's Regional Medical CenterPaterson, United StatesContact: Alissa Kahn (principal investigator)Taking people
  • Nemours Children's Clinic - PensacolaPensacola, United StatesContact: Jeffrey H. Schwartz (principal investigator)Taking people
  • OSF Children's Hospital of IllinoisPeoria, United StatesContact: Prerna Kumar (principal investigator)Taking people
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Jane E. Minturn (principal investigator)Taking people
  • Phoenix Childrens HospitalPhoenix, United StatesContact: Michael R. Mangum (principal investigator)Taking people
  • Children's Hospital of Pittsburgh of UPMCPittsburgh, United StatesContact: James T. Felker (principal investigator)Taking people
  • Legacy Emanuel Children's HospitalPortland, United StatesContact: Jason M. Glover (principal investigator)Taking people
  • Oregon Health and Science UniversityPortland, United StatesContact: Linda C. Stork (principal investigator)Taking people
  • Rhode Island HospitalProvidence, United StatesContact: Bradley DeNardo (principal investigator)Taking people
  • VCU Massey Comprehensive Cancer CenterRichmond, United StatesContact: Christopher Park (principal investigator)Taking people
  • Mayo Clinic in RochesterRochester, United StatesContact: Joseph Z. Wilson (principal investigator)Taking people
  • Corewell Health Children'sRoyal Oak, United StatesContact: Marie V. Nelson (principal investigator)Taking people
  • University of California Davis Comprehensive Cancer CenterSacramento, United StatesContact: Marcio H. Malogolowkin (principal investigator)Taking people
  • Children's Hospital of San AntonioSan Antonio, United StatesContact: Julie Voeller (principal investigator)Taking people
  • University of Texas Health Science Center at San AntonioSan Antonio, United StatesContact: Shafqat Shah (principal investigator)Taking people
  • Rady Children's Hospital - San DiegoSan Diego, United StatesContact: William D. Roberts (principal investigator)Taking people
  • UCSF Medical Center-Mission BaySan Francisco, United StatesContact: Alyssa T. Reddy (principal investigator)Taking people
  • Seattle Children's HospitalSeattle, United StatesContact: Sarah E. Leary (principal investigator)Taking people
  • Sanford USD Medical Center - Sioux FallsSioux Falls, United StatesContact: Jordan Fritch-Hanson (principal investigator)Taking people
  • Providence Sacred Heart Medical Center and Children's HospitalSpokane, United StatesContact: Judy L. Felgenhauer (principal investigator)Taking people
  • Southern Illinois University School of MedicineSpringfield, United StatesContact: Gregory P. Brandt (principal investigator)Taking people
  • Cardinal Glennon Children's Medical CenterSt Louis, United StatesContact: William S. Ferguson (principal investigator)Taking people
  • Washington University School of MedicineSt Louis, United StatesContact: Andrew S. Cluster (principal investigator)Taking people
  • Johns Hopkins All Children's HospitalSt. Petersburg, United StatesContact: Stacie L. Stapleton (principal investigator)Taking people
  • Stony Brook University Medical CenterStony Brook, United StatesContact: Rina Meyer (principal investigator)Taking people
  • State University of New York Upstate Medical UniversitySyracuse, United StatesContact: Melanie A. Comito (principal investigator)Taking people
  • Mary Bridge Children's Hospital and Health CenterTacoma, United StatesContact: Robert G. Irwin (principal investigator)Taking people
  • Saint Joseph's Hospital/Children's Hospital-TampaTampa, United StatesContact: Don E. Eslin (principal investigator)Taking people
  • Montefiore Medical Center - Moses CampusThe Bronx, United StatesContact: Alice Lee (principal investigator)Taking people
  • ProMedica Toledo Hospital/Russell J Ebeid Children's HospitalToledo, United StatesContact: Jamie L. Dargart (principal investigator)Taking people
  • New York Medical CollegeValhalla, United StatesContact: Andrew J. Bellantoni (principal investigator)Taking people
  • Children's National Medical CenterWashington D.C., United StatesContact: Jeffrey S. Dome (principal investigator)Taking people
  • Alfred I duPont Hospital for ChildrenWilmington, United StatesContact: Sridhi Patel (principal investigator)Taking people
  • Wake Forest University Health SciencesWinston-Salem, United StatesContact: Sarah Supples (principal investigator)Taking people

About the trial

What the trial wants to find out

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. Subjects with low-risk medulloblastoma typically have a lower chance of the cancer coming back than subjects with average-risk medulloblastoma. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effective at treating the cancer, there are still concerns about the side effects of such treatment. Side effects or unintended health conditions that arise due to treatment include learning difficulties, hearing loss or other issues in performing daily activities. Standard therapy for newly diagnosed average-risk or low-risk medulloblastoma includes surgery, radiation therapy, and chemotherapy (including cisplatin). Cisplatin may cause hearing loss as a side effect. In the average-risk medulloblastoma patients, this trial tests whether the addition of sodium thiosulfate (STS) to standard of care chemotherapy and radiation therapy reduces hearing loss. Previous studies with STS have shown that it may help reduce or prevent hearing loss caused by cisplatin. In the low-risk medulloblastoma patients, the study tests whether a less intense therapy (reduced radiation) can provide the same benefits as the more intense therapy. The less intense therapy may cause fewer side effects. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. The overall goals of this study are to see if giving STS along with standard treatment (radiation therapy and chemotherapy) will reduce hearing loss in medulloblastoma patients and to compare the overall outcome of patients with medulloblastoma treated with STS to patients treated without STS on a previous study in order to make sure that survival and recurrence of tumor is not worsened.

The group in the trial

  • Treatment (chemoradiotherapy, maintenance)Treatment being tested

    See Detailed Description.

    Treatment: Audiometric Test, Auditory Brainstem Response, Biospecimen Collection, Cisplatin, Cyclophosphamide, Lomustine, Magnetic Resonance Imaging, Quality-of-Life Assessment, Radiation Therapy, Sodium Thiosulfate, Survey Administration, and Vincristine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features
Plain-language title
Sodium Thiosulfate to Reduce Hearing Loss in Children With MedulloblastomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05382338, who can take part
Record updated
25 August 2026